首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1005451篇
  免费   79514篇
  国内免费   2066篇
耳鼻咽喉   15074篇
儿科学   29161篇
妇产科学   28154篇
基础医学   145630篇
口腔科学   30348篇
临床医学   87784篇
内科学   191888篇
皮肤病学   20873篇
神经病学   85150篇
特种医学   41727篇
外国民族医学   171篇
外科学   157622篇
综合类   25291篇
现状与发展   2篇
一般理论   310篇
预防医学   74807篇
眼科学   23690篇
药学   74431篇
中国医学   1813篇
肿瘤学   53105篇
  2018年   10601篇
  2017年   8567篇
  2016年   10199篇
  2015年   11047篇
  2014年   14887篇
  2013年   23006篇
  2012年   30978篇
  2011年   33003篇
  2010年   19148篇
  2009年   16880篇
  2008年   31552篇
  2007年   33952篇
  2006年   33530篇
  2005年   33016篇
  2004年   31901篇
  2003年   31028篇
  2002年   29917篇
  2001年   40361篇
  2000年   42100篇
  1999年   34194篇
  1998年   10692篇
  1997年   9747篇
  1996年   9401篇
  1995年   8788篇
  1994年   8462篇
  1992年   27287篇
  1991年   26630篇
  1990年   26109篇
  1989年   25199篇
  1988年   23659篇
  1987年   23387篇
  1986年   22142篇
  1985年   21684篇
  1984年   16973篇
  1983年   14485篇
  1982年   9371篇
  1981年   8678篇
  1979年   17099篇
  1978年   12485篇
  1977年   10586篇
  1976年   9667篇
  1975年   10506篇
  1974年   12963篇
  1973年   12404篇
  1972年   11757篇
  1971年   10910篇
  1970年   10419篇
  1969年   10090篇
  1968年   9093篇
  1967年   8416篇
排序方式: 共有10000条查询结果,搜索用时 78 毫秒
21.
22.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
23.
Sorsby fundus dystrophy (SFD), an autosomal dominant, fully penetrant, degenerative disease of the macula, is manifested by symptoms of night blindness or sudden loss of visual acuity, usually in the third to fourth decades of life due to choroidal neovascularization (CNV). SFD is caused by specific mutations in the Tissue Inhibitor of Metalloproteinase-3, (TIMP3) gene. The predominant histo-pathological feature in the eyes of patients with SFD are confluent 20–30 m thick, amorphous deposits found between the basement membrane of the retinal pigment epithelium (RPE) and the inner collagenous layer of Bruch's membrane. SFD is a rare disease but it has generated significant interest because it closely resembles the exudative or “wet” form of the more common age-related macular degeneration (AMD). In addition, in both SFD and AMD donor eyes, sub-retinal deposits have been shown to accumulate TIMP3 protein. Understanding the molecular functions of wild-type and mutant TIMP3 will provide significant insights into the patho-physiology of SFD and perhaps AMD. This review summarizes the current knowledge on TIMP3 and how mutations in TIMP3 cause SFD to provide insights into how we can study this disease going forward. Findings from these studies could have potential therapeutic implications for both SFD and AMD.  相似文献   
24.
25.
26.
27.
28.
29.
30.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号